Emmanuel Elorm Nortey-Adom
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Emmanuel Elorm Nortey-Adom has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Ajayi Oluwatomisin Temidayo
Faculty of Pharmacy, University of Lagos, Lagos, Nigeria
1 shared publication - Awoyinfa Michael Mbbs Oluwatobiloba
College of Medicine, University of Lagos, Lagos, Nigeria
1 shared publication - Chimezirim Ezeano
University of Nigeria Teaching Hospital, Ituku, Nigeria
1 shared publication - Emmanuel Kokori
University of Ilorin, Ilorin, Nigeria
1 shared publication - Gbolahan Olatunji
Department of Medicine and Surgery, University of Ilorin, Ilorin, Nigeria
1 shared publication - Israel Charles Abraham
University of Ilorin, Ilorin, Nigeria
1 shared publication
Latest Publications
- Open Access
- 25 November 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (1) , 548-553
Is there hope for HER2-positive colorectal cancer with Trastuzumab? A review of current evidence
Trastuzumab combinations are emerging as a promising therapeutic strategy for HER2-positive colorectal cancer. This review investigates the current clinical data on efficacy and safety. Clinical trials have shown encouraging results, with objective response rates (ORRs) ranging from 22.2 to 46% and complete remission achievable in some patients. Additionally, these combinations demonstrate potential for improved overall survival (OS). However, optimizing therapeutic strategies remains crucial. Future research should tailor treatment regimens based on tumor biology and individual patient characteristics. Investigating ctDNA genotyping as a reliable method for identifying responders and exploring the role of Rat Sarcoma Virus (RAS) mutations and other molecular markers are key areas for optimizing patient selection and treatment efficacy. Understanding resistance mechanisms is vital for developing combination therapies that overcome these pathways.
- 25 November 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (1) , 548-553
Open AccessIs there hope for HER2-positive colorectal cancer with Trastuzumab? A review of current evidence
Trastuzumab combinations are emerging as a promising therapeutic strategy for HER2-positive colorectal cancer. This review investigates the current clinical data on efficacy and safety. Clinical trials have shown encouraging results, with objective response rates (ORRs) ranging from 22.2 to 46% and complete remission achievable in some patients. Additionally, these combinations demonstrate potential for improved overall survival (OS). However, optimizing therapeutic strategies remains crucial. Future research should tailor treatment regimens based on tumor biology and individual patient characteristics. Investigating ctDNA genotyping as a reliable method for identifying responders and exploring the role of Rat Sarcoma Virus (RAS) mutations and other molecular markers are key areas for optimizing patient selection and treatment efficacy. Understanding resistance mechanisms is vital for developing combination therapies that overcome these pathways.